Claris Bio
Limbal stem cell deficiency (LSCD) | CSB-001
United States · $175.0M raised
- Website
- clarisbio.com
- Total Funding
- $175.0M
- Last Round
- $118.0M Series BAug 2026
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Claris Bio is a biopharmaceutical company developing therapies for sight-threatening corneal diseases with limited or no treatment options. Its lead investigational program, CSB-001, is an ophthalmic solution for limbal stem cell deficiency. The company focuses on improving outcomes for patients with corneal conditions, including wounds, ulcers, and scarring.
Summary
Claris Bio is a Biotech company based in United States. It has raised $175.0M in total across 2 rounds, most recently a $118.0M Series B round in Aug 2026. Investors include Novo Holdings A/S, Samsara BioCapital and Catalio Capital Management.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Aug 2026
Sign up to see all 2 events
Funding: Series A through Series B. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/claris-bio"><img src="https://indexed.vc/api/badge/company/claris-bio" alt="Claris Bio on Indexed.vc" width="260" height="76" /></a>